PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ: PCVX) stands against the other best mid cap biotech stocks to buy.

Investors in Vaxcyte Inc (Symbol: PCVX) saw new options begin trading today, for the January 2025 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases.

In recent trading, shares of Vaxcyte Inc (Symbol: PCVX) have crossed above the average analyst 12-month target price of $66.86, changing hands for $68.52/share. When a stock reaches the target an ...

Vaxcyte (PCVX) is scheduled to report earnings on November 4, 2024. The last reported earnings were for reported on August 6, 2024 for Q2.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases.